JPRN-jRCT2031200167已完成3 期
A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY
Kawai Norisuke0 个研究点目标入组 6,900 人开始时间: 2020年10月20日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 6,900
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 49age old（—）
- 性别
- Female
入选标准
- •Inclusion Criteria - Maternal Participants:
- •* Healthy women 18 to 49 years of age who are between 24 0/7 and 36 0/7 weeks of gestation on the day of planned vaccination, with an uncomplicated, singleton pregnancy, who are at no known increased risk for complications.
- •* Willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
- •* Receiving prenatal standard of care based on country requirements.
- •* Had an ultrasound examination performed at >=18 weeks of pregnancy with no significant fetal abnormalities observed, based on the investigator's judgment.
- •* Determined by medical history, physical examination, and clinical judgment to be appropriate for inclusion in the study.
- •* Documented negative HIV antibody test, syphilis test, and hepatitis B virus (HBV) surface antigen test during this pregnancy and prior to randomization (Visit 1).
- •* Intention to deliver at a hospital or birthing facility where study procedures can be obtained.
- •* Expected to be available for the duration of the study and can be contacted by telephone during study participation.
- •* Participant is willing to give informed consent for her infant to participate in the study.
- •* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent document (ICD) and in this protocol OR
- •* If the maternal participant is illiterate, a thumbprinted informed consent must be obtained, which must be signed and dated by an impartial witness who was present throughout the entire informed consent process confirming that the maternal participant has been informed of all pertinent aspects of the study.
- •Inclusion Criteria -Infant Participants:
- •* Evidence of a signed and dated ICD signed by the parent(s)/legal guardian(s) OR If the infant participant's maternal participant/parent(s)/legal guardian(s) is illiterate, a thumbprinted informed consent must have been obtained, which must have been signed and dated by an impartial witness who was present throughout the entire informed consent process confirming that the maternal participant/parent(s)/legal guardian(s) has been informed of all pertinent aspects of the study for herself (maternal participant) and her fetus/infant prior to taking part in the study.
- •* Parent(s)/legal guardian(s) willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.
排除标准
- •Exclusion Criteria - Maternal Participants:
- •* Prepregnancy body mass index (BMI) of >40 kg/m2. If prepregnancy BMI is not available, the BMI at the time of the first obstetric visit during the current pregnancy may be used.
- •* Bleeding diathesis or condition associated with prolonged bleeding that would, in the opinion of the investigator, contraindicate intramuscular injection.
- •* History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis) to any component of the investigational product or any related vaccine.
- •* Current pregnancy resulting from in vitro fertilization.
- •* Current pregnancy complications or abnormalities at the time of consent that will increase the risk associated with the participation in and completion of the study, including but not limited to the following:
- •* Preeclampsia, eclampsia, or uncontrolled gestational hypertension.
- •* Placental abnormality.
- •* Polyhydramnios or oligohydramnios.
- •* Significant bleeding or blood clotting disorder.
- •* Endocrine disorders, including untreated hyperthyroidism or untreated hypothyroidism. This also includes disorders of glucose intolerance (eg, diabetes mellitus type 1 or 2) antedating pregnancy or occurring during pregnancy if uncontrolled at the time of consent.
- •* Any signs of premature labor with the current pregnancy or having ongoing intervention (medical/surgical) in the current pregnancy to prevent preterm birth.
- •* Prior pregnancy complications or abnormalities at the time of consent, based on the investigator's judgment, that will increase the risk associated with the participation in and completion of the study, including but not limited to the following:
- •* Prior preterm delivery <=34 weeks' gestation.
- •* Prior stillbirth or neonatal death.
- •* Previous infant with a known genetic disorder or significant congenital anomaly.
- •* Major illness of the maternal participant or conditions of the fetus that, in the investigator's judgment, will substantially increase the risk associated with the maternal participant's participation in, and completion of, the study or could preclude the evaluation of the maternal participant's response.
- •* Congenital or acquired immunodeficiency disorder, or rheumatologic disorder or other illness requiring chronic treatment with known immunosuppressant medications, including monoclonal antibodies, within the year prior to enrollment.
- •* Other acute or chronic medical or psychiatric condition including recent (within the past year) or active suicidal ideation or behavior or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
- •* Participation in other studies involving investigational drug(s) within 28 days prior to consent and/or during study participation.
- •* Receipt of monoclonal antibodies within the year prior to enrollment or the use of systemic corticosteroids for >14days within 28 days prior to study enrollment. Prednisone use of <20 mg/day for <=14 days is permitted.
- •Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
- •Inhaled/nebulized, intra-articular, intrabursal, or topical (skin or eyes) corticosteroids are permitted.
- •* Current alcohol abuse or illicit drug use.Country-Specific Appendix-Applicable t
研究者
相似试验
已完成
不适用
A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF ARQ 197 PLUS ERLOTINIB VERSUS PLACEBO PLUS ERLOTINIB IN PREVIOUSLY TREATED SUBJECTS WITH LOCALLY ADVANCED OR METASTATIC, NON-SQUAMOUS, NON-SMALL-CELL LUNG CANCER (NSCLC)PER-025-11DAIICHI SANKYO PHARMA DEVELOPMENT,11
进行中（未招募）
1 期
A TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCYPrevention of medically attended Respiratory Syncytial Virus-associated lower respiratory tract illness (LRTI) in infants by active immunization of pregnant womenMedDRA version: 21.1Level: LLTClassification code 10066742Term: Respiratory syncytial virus infection prophylaxisSystem Organ Class: 100000004865EUCTR2019-002943-85-DKPfizer Inc10,000
进行中（未招募）
1 期
A TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCYEUCTR2019-002943-85-NLPfizer Inc., 235 East 42nd Street, New York, NY 100176,900
已完成
3 期
A PHASE 3, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY Short title: A Phase 3 Trial to Evaluate the Efficacy and Safety of RSVpreF in Infants Born to Women Vaccinated During Pregnancy.NL-OMON52627Pfizer217
未知
不适用
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE-TITRATION STUDY TO ASSESS THE EFFICACY, SAFETY AND PHARMACOKINETICS OF INTRAVENOUS CONIVAPTAN (VAPRISOL®) IN PEDIATRIC SUBJECTS WITH EUVOLEMIC OR HYPERVOLEMIC HYPONATREMIAPER-027-12Astellas Pharma Global Development, Inc. (APGD-US),